LLY
1,072.27
+1.4%↑
JNJ
206
-1.09%↓
ABBV
227.14
+1.9%↑
UNH
327.43
-0.31%↓
AZN
91.35
+0.79%↑
LLY
1,072.27
+1.4%↑
JNJ
206
-1.09%↓
ABBV
227.14
+1.9%↑
UNH
327.43
-0.31%↓
AZN
91.35
+0.79%↑
LLY
1,072.27
+1.4%↑
JNJ
206
-1.09%↓
ABBV
227.14
+1.9%↑
UNH
327.43
-0.31%↓
AZN
91.35
+0.79%↑
LLY
1,072.27
+1.4%↑
JNJ
206
-1.09%↓
ABBV
227.14
+1.9%↑
UNH
327.43
-0.31%↓
AZN
91.35
+0.79%↑
LLY
1,072.27
+1.4%↑
JNJ
206
-1.09%↓
ABBV
227.14
+1.9%↑
UNH
327.43
-0.31%↓
AZN
91.35
+0.79%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 17.383 76.798 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 73M 1.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +196.3% upside |
Market Cap | -113M 460M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 196.3%
High 26 USD
Low 21 USD
Based on 6 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
6
Buy
0
Hold
0
Sell
Based on 6 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$